Transcatheter arterial infusion chemotherapy using cisplatin powder and iodized-oil for advanced hepatocellular carcinoma: a phase 2 study - HCC-CDDP+Lipiodol-P2

Japan Society of Transcatheter Hepatic Arterial Embolization Clinical Reserch Group0 个研究点目标入组 35 人开始时间: 2011年4月25日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)History of previous treatment by platinum drugs. 2)Extrahepatic metastasis. 3)Advanced vascular or biliary invasion (Vp4,Vv3,B3,B4). 4)Sever arterio-portal shunt or arterio-venous shunt. 5)Difficult to perform transcatheter arterial chemotherapy. 6)History of the biliary tract reconstruction or treatment. 7)Patients with following severe complicating disease(except chronic hepatitis and liver cirrhosis). 1.Heart failure 2.Renal failure 3.Active infections(except viral hepatitis) 4.Active gastrointestinal bleeding 5.Active duplicative cancer 6.Hepatic encephalopathy or severe mental illness 8)Fever >= 38.0 degrees Celsius. 9)History of hypersensitivity to iodine-containing contrast agent, gadolinium-containing contrast agent, and platinum-containing drug. 10)Patients who are pregnant, lactating, suspected to be pregnant, or wish to become pregnant. 11)Patients who are concluded to be inappropriate to participate in this study by their physicians.

发起方

Japan Society of Transcatheter Hepatic Arterial Embolization Clinical Reserch Group